Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

NCT06840834 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Pleural Mesotheliomas

Interventions

DRUG: Ivonescimab

Sponsor

Intergroupe Francophone de Cancerologie Thoracique

Collaborators

[object Object]